Page 12 - Servier Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Servier to acquire Agios’ oncology business in $1.8bn deal French pharma will also gain Agios' oncology-associated employees French pharma Servier has announced that it will acquire Agios Pharmaceuticals’ oncology business unit which includes it entire commercial, clinical and research-stage oncology portfolio. Under the terms of the deal, Servier will make an upfront payment of $1.8bn, with a potential $200m earmarked for regulatory milestone payments, plus royalties. The deal reflects Servier’s re-focus on its core business strategy, which includes oncology as a major area of interes...

PARIS and MONTREAL, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Servier, an international pharmaceutical company, announces the opening of a worldwide Artificial Intelligence (AI) Hub in Montreal, in partnership with Centech, a deep-tech business incubator recognized as one of the most successful university incubators in the world. The creation of Servier’s Artificial Intelligence Hub occurs within the framework of the ambitious digital transformation project undertaken by the Group, as they are convinced of the key position that digitalization must have in their activities, and the growing role o...

Published: Dec 21, 2020 CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that it will move forward with a singular focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates, and has entered into a definitive agreement to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceu...

Cambridge biotech Agios will sell oncology business to Boston’s Servier for up to $2 billion The seller aims to focus on new therapies for genetic diseases By Anissa Gardizy Globe Staff,Updated December 21, 2020, 7:00 a.m. Email to a Friend Agios Pharmaceuticals Inc. has agreed to sell its oncology business to Boston’s Servier Pharmaceuticals in a deal worth up to $2 billion. Agios, of Cambridge, which has two cancer drugs on the market and others in testing, said Monday that it has decided to focus on drugs it is developing for genetic diseases. That portfolio is anchored by a med...

CET- Comunicado - ";ultimaHoraHtml += " " + json.lead + "";}ultimaHoraHtml += ""; document.getElementById("urgente").innerHTML = ultimaHoraHtml; } } }); - Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 billion plus royalties - Includes Agios' marketed medicine TIBSOVO(®) and a strong oncology pipeline of Phase 3 and early-stage assets - Acquisition in-line with Servier's strategic ambition to become a recognized and innovative player in oncology, supported by unique drug discovery capabilities...